Additionally, the identification of alkylated MGMT and MGMT inhibitors promoting the degradation of BRCA2 presents a promising strategy for targeting homologous recombination proficient cancers with MGMT inactivators in conjunction with DNA crosslinking agents [236]. Here, BRCA2 is linked to cancer.